Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14430962 | 0.88 | GCK (0.82) | GCKKDM4EMAPK1LMNANPC1 | |
| SCHEMBL2642521 | 0.83 | GCK (0.73) | GCKALDH1A1KDM4EMAPK1LMNA | |
| SCHEMBL2643117 | 0.78 | GCK (1.00) | GCKKDM4ENPC1RAB9A | |
| SCHEMBL2643455 | 0.75 | GCK (0.82) | GCKKDM4ENPC1RAB9A | |
| SCHEMBL2643904 | 0.74 | GCK (0.83) | GCKKDM4ENPC1RAB9A | |
| SCHEMBL2643522 | 0.72 | GCK (0.84) | GCK | |
| SCHEMBL2643624 | 0.72 | GCK (0.74) | GCKALDH1A1KDM4EMAPK1LMNA | |
| SCHEMBL2643912 | 0.71 | GCK (0.84) | GCK | |
| SCHEMBL2642881 | 0.71 | GCK (0.52) | GCKKDM4ELMNANPC1RAB9A | |
| SCHEMBL2643426 | 0.71 | GCK (0.61) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496052-B1 | NOVEL AMINOBENZAMIDE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-7253188-B2 | Aminobenzamide derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20050282815-A1 | Novel aminobenzamide derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1496052-A1 | NOVEL AMINOBENZAMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282815-A1 | Novel aminobenzamide derivative | GCKR, GCK, HK2 | GCK 2/4885ALDH1A1 1496/4885PDE5A 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.